VGA039

· Vega Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for VGA039, covering 2025-08-26 to 2026-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) [Phase 3]